United States - English - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see warnings and precautions (5.1)] . valproic acid is contraindicated in patients with known hypersensitivity to the drug [see warnings and precautions (5.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings for statement regarding fatal hepatic dysfunction. valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction. valproic acid is contraindicated in patients with known hypersensitivity to the drug. valproic acid is contraindicated in patients with known urea cycle disorders (see warnings

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings for statement regarding fatal hepatic dysfunction. valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction. valproic acid is contraindicated in patients with known hypersensitivity to the drug. valproic acid is contraindicated in patients with known urea cycle disorders (see warnin

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the ma

Canada - English - Health Canada

apotex inc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

pharmascience inc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

pharmel inc - valproic acid (sodium valproate) - syrup - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

dominion pharmacal - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

apotex inc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid capsules are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid capsules are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is